Skip to content

+1 877 566 4981

info@fdamap.com

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us
Contact Us
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us

Day: August 31, 2023

What You Should Know About the $1 Billion Taxpayer-Funded Covid Trial

April 29, 2025August 31, 2023 by Prahsant Kumar

The US government is investing heavily in finding new COVID-19 vaccines both to treat acute infections and to treat long-term side effects of Covid, called Long Covid. In that regard, the US Department of Health and Human Services (HHS) announced an award of $1.4 billion for its latest efforts of which $1 billion will be … Read more

Categories Blog

FDA Releases Expectations for Using RWE in Support of New Drug Approvals

April 29, 2025August 31, 2023 by Prahsant Kumar

Real World Data (RWD) collected from medical records and the Real World Evidence (RWE) generated from it can be used to seek market approval for new uses of FDA-approved products by the FDA. However, there are specific FDA requirements for the quality and integrity of the RWD before its acceptance by the FDA. A new … Read more

Categories Blog

Recent Posts

  • FDA’s Transition to a Unified Adverse Event Framework
  • De-risking Drug Development with Fit-for-Purpose Non-Animal Models
  • Navigating the New Regulatory Framework for Biosimilars: FDA Slashes PK Hurdles and Streamlines the Biosimilar Pipeline
  • Strategic Response Management: Aligning 483 Remediation
  • Unlocking the FDA’s 3-Year Exclusivity: What Drug Developers Need to Know

Recent Comments

No comments to show.

One-stop source for FDA consultation, regulatory affairs training, and clinical trial services.

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin

Services

  • Webinars
  • Workshops
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions

Company

  • About Us
  • Our Client
  • Testimonials
  • Free Resources
  • Newsletter

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy

Payment Method

100% Secure Transaction

Copyright © 2025 FDAMap.com. All rights reserved.